The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Open accessAbstract
Cancer cells have metabolic dependencies that distinguish them from their normal counterparts. Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes. Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into α-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [73]
In the citing paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [57]
In the citing paper
“Mouse PDAC tumors driven by mutant Kras also experience metabolic alteration and are dependent on glucose and glutamine (73, 77).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [77]
In the citing paper
“combining inhibition of glycolysis with blockade of KRAS effector signaling pathways has shown efficacy in culture and xenograft models197”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“However, under normal and glucose-replete conditions, transamination is the dominant reaction that drives glutamine anaplerosis in cultured cells (79, 80, 81, 82).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,004
Ushio‐Fukai, M., Ash, D., Nagarkoti, S., de Chantemèle, E. J. B., Fulton, D. J., & Fukai, T. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8161 · Cited by 99
Glutamine addiction in tumor cell: oncogene regulation and clinical treatment
Li, X., Peng, X., Li, Y., Wei, S., He, G., Liu, J., Li, X., Yang, S., Dai, L., Lin, W., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01449-x · Cited by 103
Altered glutamine metabolism in platinum resistant ovarian cancer
Hudson, C. D., Savadelis, A., Nagaraj, A. B., Joseph, P. L., Avril, S., DiFeo, A. V., & Avril, N. E. (2016) · Oncotarget · doi:10.18632/oncotarget.9317 · Cited by 95
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review
Fakhri, S., Moradi, S. Z., Farzaei, M. H., & Bishayee, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.007 · Cited by 97
Vaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 102
Yuan, M., Tu, B., Li, H., Pang, H., Zhang, N., Fan, M., Bai, J., Wang, W., Shu, Z., DuFort, C. C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00426-6 · Cited by 98
Self-citationLee, P., Vousden, K. H., & Cheung, E. C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-1 · Cited by 99
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 94
Glutamine‐utilizing transaminases are a metabolic vulnerability of TAZ/YAP‐activated cancer cells
Yang, C., Stampouloglou, E., Kingston, N. M., Zhang, L., Monti, S., & Varelas, X. (2018) · EMBO Reports · doi:10.15252/embr.201643577 · Cited by 97
Prognostic role of glycolysis for cancer outcome: evidence from 86 studies
Yu, M., Chen, S., Hong, W., Gu, Y., Huang, B., Lin, Y., Zhou, Y., Jin, H., Deng, Y., Tu, L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02847-w · Cited by 94
Hyaluronic acid fuels pancreatic cancer cell growth
Kim, P. K., Halbrook, C. J., Kerk, S. A., Radyk, M., Wisner, S., Kremer, D. M., Sajjakulnukit, P., Andren, A., Hou, S. W., Trivedi, A., et al. (2021) · eLife · doi:10.7554/elife.62645 · Cited by 92
Self-citationCheng, G., Zielonka, J., McAllister, D. M., Tsai, S., Dwinell, M. B., & Kalyanaraman, B. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.272 · Cited by 90
Applications of Metabolomics in Cancer Studies
Armitage, E. G., & Ciborowski, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-47656-8_9 · Cited by 94
Zhu, Y., Li, T., da Silva, S. R., Lee, J. J., Lu, C., Eoh, H., Jung, J. U., & Gao, S. (2017) · mBio · doi:10.1128/mbio.01179-17 · Cited by 92
Murthy, D., Attri, K. S., & Singh, P. K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00335 · Cited by 96
Wang, J., Wang, B., Ren, H., & Chen, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.114 · Cited by 91
Glutaminases regulate glutathione and oxidative stress in cancer
Matés, J. M., Campos-Sandoval, J. A., de los Santos-Jiménez, J., & Márquez, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02838-8 · Cited by 91
In cancer, all roads lead to NADPH
Rather, G. M., Pramono, A. A., Székely, Z., Bertino, J. R., & Tedeschi, P. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107864 · Cited by 91
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
Remacha, L., Comino‐Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, A., Torres‐Pérez, R., Honrado, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2250 · Cited by 98
Pei, Y., Liang, C., Huang, Y., Wang, J., Feng, J., Xu, M., Chen, Y., Song, Q., Jiang, G., Gu, X. Q., et al. (2019) · Small · doi:10.1002/smll.201900631 · Cited by 91
Shen, Y., Hong, J., Asaka, R., Asaka, S., Hsu, F., Rahmanto, Y. S., Jung, J.-G., Chen, Y.-W., Yen, T., Tomaszewski, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3971 · Cited by 91
Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe?
Koju, N., Qin, Z., & Sheng, R. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00838-7 · Cited by 97
Metabolic dependencies and vulnerabilities in leukemiaPreprint
Rashkovan, M., & Ferrando, A. A. (2019) · Genes & Development · doi:10.1101/gad.326470.119 · Cited by 92
Zeng, B., Ye, H., Chen, J., Cheng, D., Cai, C., Chen, G., Chen, X., Xin, H., Tang, C., & Zeng, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21922 · Cited by 89
Daemen, A., Liu, B., Song, K., Kwong, M., Gao, M., Hong, R., Nannini, M., Peterson, D., Liederer, B. M., de la Cruz, C., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.003 · Cited by 88
Katagiri, R., Goto, A., Nakagawa, T., Nishiumi, S., Kobayashi, T., Hidaka, A., Budhathoki, S., Yamaji, T., Sawada, N., Shimazu, T., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.033 · Cited by 89
Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response
McCann, E., O'Sullivan, J. N., & Marcone, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100905 · Cited by 89
Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap
Halama, A., & Suhre, K. (2022) · Cancers · doi:10.3390/cancers14030553 · Cited by 93
Martín‐Rufián, M., Nascimento-Gomes, R., Higuero, A., Crisma, A. R., Campos-Sandoval, J. A., Gómez-García, M. C., Cardona, C., Cheng, T., Lobo, C., Segura, J. A., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1105-2 · Cited by 88
Huang, B., Cheng, X., Wang, D., Peng, M., Xue, Z., Da, Y., Zhang, N., Yao, Z., Li, M., Xu, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1963 · Cited by 89
Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
Guillaumond, F., Iovanna, J., & Vasseur, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.12.019 · Cited by 90
Targeting hypoxic response for cancer therapy
Paolicchi, E., Gemignani, F., Krstic–Demonacos, M., Dedhar, S., Mutti, L., & Landi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7229 · Cited by 93
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 92
Gangi, I. M. D., Mazza, T., Fontana, A., Copetti, M., Fusilli, C., Ippolito, A. M., Mattivi, F., Latiano, A., Andriulli, A., Vrhovšek, U., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6808 · Cited by 88
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Tran, T. Q., Lowman, X. H., & Kong, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2506 · Cited by 91
dos Reis, L. M., Adamóski, D., Souza, R. O. O., Ascenção, C. F. R., de Oliveira, K. R. S., Corrêa‐da‐Silva, F., Patroni, F. M. D. S., Dias, M. M., Consonni, S. R., Moraes‐Vieira, P. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008180 · Cited by 88
Reactive oxygen species in cancer progression and its role in therapeutics
Singh, R. K., & Manna, P. P. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00073 · Cited by 93
Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
Bernfeld, E., & Foster, D. A. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.03.003 · Cited by 85
Metabolic Dependencies in Pancreatic Cancer
Gohar, A. V., Zarei, M., Brody, J. R., & Winter, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00617 · Cited by 87
Targeting GLS1 to cancer therapy through glutamine metabolism
Yu, W., Yang, X., Zhang, Q., Sun, L., Yuan, S., & Xin, Y. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02645-2 · Cited by 86
Li, Y., Li, B., Xu, Y., Qian, L., Xu, T., Meng, G., Li, H., Wang, Y., Zhang, L., Jiang, X. W., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0042 · Cited by 90
Redox signaling in the pancreas in health and disease
Sastre, J., Pérez, S., Sabater-Orti, L., & Rius‐Pérez, S. (2024) · Physiological Reviews · doi:10.1152/physrev.00044.2023 · Cited by 101
Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy
Jia, X., Wang, Y., Qiao, Y., Jiang, X., & Li, J. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00404c · Cited by 87
Stalnecker, C. A., Ulrich, S. M., Li, Y., Ramachandran, S., McBrayer, M. K., DeBerardinis, R. J., Cerione, R. A., & Erickson, J. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414056112 · Cited by 87
Patel, D., Menon, D., Bernfeld, E., Mroz, V., Kalan, S., Loayza, D., & Foster, D. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710145 · Cited by 86
Wu, D., Zhuo, L., & Wang, X. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.11.003 · Cited by 88
Self-citationHRAS‐driven cancer cells are vulnerable to TRPML1 inhibition
Jung, J., Cho, K., Naji, A. K., Clemons, K., Wong, C., Villanueva, M., Gregory, S., Karagas, N. E., Tan, L., Hong, L., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846685 · Cited by 85
Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells
Wang, K., Zhang, Z., Wang, M., Cao, X., Qi, J., Wang, D., Gong, A., & Zhu, H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s199459 · Cited by 87
Emerging mechanisms and promising approaches in pancreatic cancer metabolism
Wu, H., Fu, M., Wu, M., Cao, Z., Zhang, Q., & Liu, Z. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06930-0 · Cited by 97
Gouda, M. A., Voss, M. H., Tawbi, H. A., Gordon, M. S., Tykodi, S. S., Lam, E. T., Vaishampayan, U. N., Tannir, N. M., Chaves, J. M., Nikolinakos, P. G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104536 · Cited by 88
Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
Shanware, N. P., Bray, K., Eng, C. H., Wang, F., Follettie, M. T., Myers, J. S., Fantin, V. R., & Abraham, R. T. (2014) · Nature Communications · doi:10.1038/ncomms5900 · Cited by 86
Functional annotation of rare gene aberration drivers of pancreatic cancer
Tsang, Y. H., Dogruluk, T., Tedeschi, P. M., Wardwell‐Ozgo, J., Lu, H., Espitia, M., Nair, N. V., Minelli, R., Chong, Z., Chen, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms10500 · Cited by 84
Self-citationThe role of RNA alternative splicing in regulating cancer metabolism
Kozlovski, I., Siegfried, Z., Amar-Schwartz, A., & Karni, R. (2017) · Human Genetics · doi:10.1007/s00439-017-1803-x · Cited by 83
Okazaki, S., Umene, K., Yamasaki, J., Suina, K., Otsuki, Y., Yoshikawa, M., Minami, Y., Masuko, T., Kawaguchi, S., Nakayama, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14182 · Cited by 85
The emerging role of metabolism in fibrosis
Henderson, J., & O’Reilly, S. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.05.003 · Cited by 87
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 98
Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch
Lee, S. Y., Jeon, H. M., Ju, M. K., Jeong, E. K., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2016) · Oncotarget · doi:10.18632/oncotarget.6879 · Cited by 82
Oncogene-Driven Metabolic Alterations in Cancer
Min, H., & Lee, H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.211 · Cited by 88
Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
Hedberg, M. L., Berry, C. T., Moshiri, A. S., Xiang, Y., Yeh, C. J., Atillasoy, C., Capell, B. C., & Seykora, J. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073478 · Cited by 94
Huang, H., Wang, S., Xia, H., Zhao, X., Chen, K., Jin, G., Zhou, S., Lu, Z., Chen, T., Yu, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216806 · Cited by 90
Sirtuins and the Metabolic Hurdles in Cancer
German, N. J., & Haigis, M. C. (2015) · Current Biology · doi:10.1016/j.cub.2015.05.012 · Cited by 84
Self-citationAutophagy is required for PDAC glutamine metabolism
Seo, J., Choi, J., Lee, S., Sung, S., Yoo, H. J., Kang, M., Cheong, H., & Son, J. (2016) · Scientific Reports · doi:10.1038/srep37594 · Cited by 86
Self-citationNature and Nurture: What Determines Tumor Metabolic Phenotypes?
Mayers, J. R., & Heiden, M. G. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0165 · Cited by 86
Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment
Hawk, M. A., & Schafer, Z. T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm117.000260 · Cited by 82
Murakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.022 · Cited by 83
Bartolacci, C., Andreani, C., Elgammal, Y., & Scaglioni, P. P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.706650 · Cited by 86
Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma
Ratnikov, B. I., Aza‐Blanc, P., Ronai, Z. A., Smith, J. W., Osterman, A. L., & Scott, D. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3132 · Cited by 80
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
Brunelli, L., Caiola, E., Marabese, M., Broggini, M., & Pastorelli, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1958 · Cited by 82
Murai, S., Ando, A., Ebara, S., Hirayama, M., Satomi, Y., & Hara, T. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.34 · Cited by 83
Klomp, J. E., Klomp, J. A., & Der, C. J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200507 · Cited by 85
Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance
Lyssiotis, C. A., Son, J., Cantley, L. C., & Kimmelman, A. C. (2013) · Cell Cycle · doi:10.4161/cc.25307 · Cited by 83
Self-citationKRas, ROS and the initiation of pancreatic cancer
Storz, P. (2017) · Small GTPases · doi:10.1080/21541248.2016.1192714 · Cited by 82
Hu, L., Liu, J., Zhang, W., Wang, T., Zhang, N., Lee, Y. H., & Lu, H. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21611 · Cited by 81
Fujimura, K., Choi, S., Wyse, M. M., Strnádel, J., Wright, T., & Klemke, R. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.687418 · Cited by 82
Wilmanski, T. M., Zhou, X., Zheng, W., Shinde, A. B., Donkin, S. S., Wendt, M. K., Burgess, J. R., & Teegarden, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.045 · Cited by 81
Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
Lau, A. N., Li, Z., Danai, L. V., Westermark, A. M., Darnell, A. M., Ferreira, R., Gocheva, V., Sivanand, S., Lien, E. C., Sapp, K. M., et al. (2020) · eLife · doi:10.7554/elife.56782 · Cited by 82
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Reyes‐Castellanos, G., Masoud, R., & Carrier, A. (2020) · Biomedicines · doi:10.3390/biomedicines8080270 · Cited by 85
Li, M., Thorne, R. F., Shi, R., Zhang, X. D., Li, J., Li, J., Zhang, Q., Wu, M., & Liu, L. (2021) · Advanced Science · doi:10.1002/advs.202003732 · Cited by 81
MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype
Tambay, V., Raymond, V., & Bilodeau, M. (2021) · Cancers · doi:10.3390/cancers13174484 · Cited by 91
García‐Bermúdez, J., Badgley, M. A., Prasad, S., Baudrier, L., Liu, Y., La, K., Soula, M., Williams, R. T., Yamaguchi, N., Hwang, R. F., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00583-z · Cited by 86
Targeting reactive oxygen species in development and progression of pancreatic cancer
Durand, N., & Störz, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1261017 · Cited by 79
Halbrook, C. J., Thurston, G., Boyer, S., Anaraki, C., Jiménez, J. A., McCarthy, A., Steele, N. G., Kerk, S. A., Hong, H. S., Lin, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00463-1 · Cited by 80
Self-citationPPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC
Kim, M. J., Choi, Y., Park, S. Y., Jang, S. Y., Lee, J. Y., Ham, H. J., Kim, B., Jeon, H., Kim, J. H., Kim, J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0061 · Cited by 82
Liang, C., Shi, S., Liu, M., Qin, Y., Meng, Q., Hua, J., Ji, S., Zhang, Y., Yang, J., Xu, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1968 · Cited by 80
Franchi, L., Monteleone, I., Hao, L.-Y., Spahr, M. A., Zhao, W., Liu, X., Demock, K. M., Kulkarni, A., Lesch, C. A., Sanchez, B., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600810 · Cited by 79
Self-citationMa, G., Liang, Y., Chen, Y., Wang, L., Li, D., Liang, Z., Wang, X., Tian, D., Yang, X., & Niu, H. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0517 · Cited by 82
Self-citationAspartate availability limits hematopoietic stem cell function during hematopoietic regeneration
Qi, L., Martin-Sandoval, M. S., Merchant, S., Gu, W., Eckhardt, M., Mathews, T. P., Zhao, Z., Agathocleous, M., & Morrison, S. J. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.07.011 · Cited by 85
Recouvreux, M. V., Grenier, S. F., Zhang, Y., Esparza, E., Lambies, G., Galapate, C. M., Maganti, S., Duong‐Polk, K., Bhullar, D., Naeem, R. F., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00649-1 · Cited by 79
Wang, X., Ding, B., Liu, W., Qi, L., Li, J., Zheng, X., Song, Y., Li, Q., Wu, J., Zhang, M., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c03478 · Cited by 80
Self-citationEstablishment of local searching methods for orbitrap-based high throughput metabolomics analysis
Tang, H., Wang, X., Xu, L., Ran, X., Li, X., Chen, L., Zhao, X., Deng, H., & Liu, X. (2016) · Talanta · doi:10.1016/j.talanta.2016.04.051 · Cited by 79
Self-citationVerdon, Q., Boonen, M., Ribes, C., Jadot, M., Gasnier, B., & Sagné, C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617066114 · Cited by 85
Metabolism during ECM Detachment: Achilles Heel of Cancer Cells?
Mason, J. A., Hagel, K. R., Hawk, M. A., & Schafer, Z. T. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.009 · Cited by 78
Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer
Toda, K., Nishikawa, G., Iwamoto, M., Itatani, Y., Takahashi, R., Sakai, Y., & Kawada, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081632 · Cited by 77
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.
Zhang, X., Shi, S., Zhang, B., Ni, Q., Yu, X., & Xu, J. (2018) · PubMed Central · Cited by 78
Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion
Mestre‐Farrera, A., Bruch‐Oms, M., Peña, R., Rodríguez-Morató, J., Alba‐Castellón, L., Comerma, L., Quintela-Fandiño, M., Duñach, M., Baulida, J., Pozo, Ó. J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0622 · Cited by 81
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 78
Pancreatic cancer cachexia: three dimensions of a complex syndrome
Kordes, M., Larsson, L., Engstrand, L., & Löhr, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01301-4 · Cited by 83
Okazaki, S., Shintani, S., Hirata, Y., Suina, K., Semba, T., Yamasaki, J., Umene, K., Ishikawa, M., Saya, H., & Nagano, O. (2018) · Oncotarget · doi:10.18632/oncotarget.26112 · Cited by 81
Metadata
- Authors
- Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Corresponding author
- Cantley, Lewis C.
- Kimmelman, Alec C.
- ORCID
- Venue
- Nature
- Published
- 2013-03-27
- Volume
- 496
- Issue
- 7443
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656466
- OpenAlex
- W2014988241
- Cited by
- 1,990
- References
- 27
- Citations by year
- 2026: 130 · 2025: 143 · 2024: 138 · 2023: 169 · 2022: 193 · 2021: 209 · 2020: 169 · 2019: 162 · 2018: 141 · 2017: 144 · 2016: 152 · 2015: 112 · 2014: 95 · 2013: 31
- FWCI
- 45.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009382, R01CA157490, P01CA120964, P01CA117969, P30CA006516)
- National Institute of General Medical Sciences (R01GM056203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, glutamine metabolism, KRAS, tumor metabolic reprogramming, oxaloacetate, NADPH/NADP+ ratio, redox homeostasis, glutamine deprivation, reactive oxygen species, glutathione, tumor growth
- MeSH terms
- Adenocarcinoma, Aspartate Aminotransferases, Citric Acid Cycle, Glutamate Dehydrogenase, Glutamine, Homeostasis, Humans, Ketoglutaric Acids, Oncogenes, Oxidation-Reduction, Pancreatic Neoplasms, Proto-Oncogene Proteins, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Reactive Oxygen Species, ras Proteins, Cell Line, Tumor, Cell Proliferation, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
